Bone Biologics Corp.
13F holders, Q1 2025 (March 31)4holders −3
0new positions
3sold out
$0.80avg. 13F price*
At the end of Q1 2025, 4 institutions reported holding Bone Biologics Corp. in their 13F filings, down 3 from Q4 2024. 0 opened new positions and 3 sold out. The largest holders were Geode Capital Management, LLC ($19K), Tower Research Capital LLC (TRC) ($1K) and Bank of America Corp. ($17).
- Company
- Bone Biologics Corp.
- CUSIP
- 098070501
- Latest filing quarter
- Q1 2025
History
Number of 13F holders
Total Exit/New Position Q4 2024 → Q1 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 3 | $38K |
All 13F filers, Q4 2024 → Q1 2025: 8,850 shares bought and 43,035 shares sold, net −34,185 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 4 holders
| Geode Capital Management, LLC | 0.00% | Add +57.6% | 24,204 | $19K |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -46.1% | 1,824 | $1K |
| Bank of America Corp. | 0.00% | Add +5.0% | 21 | $17 |
| SBI Securities Co., Ltd. | 0.00% | No change | 1 | $1 |
"% of holder's portfolio" is BONE BIOLOGICS CORP's weight in each manager's 13F, not the share of Bone Biologics Corp. the manager owns.